摘要
目的探讨18F-FDG PET显像评价乳腺癌新辅助化疗疗效应用价值。方法对31例经细针穿刺或针吸细胞活检确诊为原发性乳腺癌的患者在FAC方案化疗前、后分别行18F-FDG PET显像,根据PET显像结果计算乳腺癌病灶放射性摄取比值(T/NT);3个疗程结束后评价疗效,以WHO制定的肿瘤化疗评价标准分为有效组[R(+),n=22]和无效组[R(-),n=9];以第3疗程结束后T/NT比值降低百分率≥10%、≥20%、≥30%作为监测治疗有无反应的阈值进行疗效判定。结果化疗前R(+)组和R(-)组T/NT比值分别为3.18±0.41、3.14±0.52(P>0.05),化疗第3疗程后R(+)组T/NT比值从3.18±0.41降低为2.06±0.45(P<0.05),而R(-)组T/NT比值从3.14±0.52降低为2.87±0.27(P>0.05);R(+)组T/NT比值降低的百分率为(33.42±6)%,明显高于R(-)组(8.89±6)%(P<0.01);若以第3疗程结束后T/N比值降低百分率≥10%、≥20%、≥30%作为监测治疗有无反应的阈值,18F-FDG PET评价疗效的灵敏度、特异性分别为100%、89%、82%和85%、92%、100%。结论18F-FDG
Objective To study the application value of response to neoadjuvant chemotherapy in breast cancer using ^18F-fluorodeoxyglucose（FDG） positron emission tomography（PET）.Methods Thirty-one primary breast cancer patients finally diagnosed by fine needle aspiration examination accepted ^18F-FDG PET imaging examination before and after three cycles of FAC chemotherapy.Calculation was carried out for the tumor-to-normal tissue background（T/NT） value in the focus of the cancer.According to WHO criterion,the patients were divided into two groups after therapy,i.e.effective group ／ and non-effective group ／.According to the T/NT declining percentage（such as≥10%,≥20% and ≥30%）,the patients＇curative effects were evaluated respectively.Results The T/NT values of group R（＋） and group R（-） were respectively 3.18±0.41 and 3.14＋0.52（P〉0.05） before chemotherapy.After chemotherapy the T/NT of group R（＋） went down to 2.06±0.45（P〈0.05）,and the T/NT of group R（-） down to 2.87±0.27（P〉0.05）.The declining percentage of R（＋） was 33.42%±6%,obviously higher than that of R（-） group（8.89%±6%,P〈0.05）.Based on the declining percentage of T/NT（≥10%,≥20% and ≥30%）,the sensitivity and specificity of ^18F-FDG PET were 100%,89%,82%（sensitivity）,and 85%,92% and 100%（specificity）,respectively.Conclusion ^18F-FDG PET imaging has clinically applicable value for earlier curative effect assessment to neoadjuvant chemotherapy in breast cancer.
出处
《临床军医杂志》
CAS
2007年第6期820-822,共3页
Clinical Journal of Medical Officers
关键词
^18F-FDG
乳腺肿瘤
新辅助化疗
疗效
^18F-fluorodeoxyglucose
breast cancer
neoadjuvant chemotherapy
curative effect
